May 17, 2010 (Orlando, Florida) — Patients with Parkinson's disease dementia (PDD) given oral rivastigmine for 24 weeks showed improvement on all symptom domains of the Alzheimer's Disease Assessment ...
Showing that an experimental Alzheimer’s therapy delivers meaningful cognitive change is hard enough. But increasingly, AD drug sponsors face an additional challenge: making sure the tests capturing ...
Cassava Sciences Inc SAVA announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback